Tuberc Respir Dis > Volume 21(2); 1974 > Article
Tuberculosis and Respiratory Diseases 1974;21(2):85-95.
DOI: https://doi.org/10.4046/trd.1974.21.2.85    Published online June 1, 1974.
Drug Resistance of M. tuberculosis Isolated from Patients Discovered In The Second National Tuberculosis Prevalence Survey
Sung Chin Kim, Sang Jae Kim, Kyu Jeong Lee
The Korean Institute of Tubereulosis KNTA
제2차 결핵 실태조사에서 분리한 결핵균의 각종 항결핵제에 대한 감수성에 관한 연구
김성진, 김상재, 이규정
Abstract
Sensitivity tests to anti-tuberculosis standard and second line drugs were carried out on a total of 132 cultures of M. t u tuberculosis which were obtained from patients discovered in the Second National Tuberculosis Survey (1970) in Korea. Using the British MRC-Standard Method with the following concentrations (μg/ml) for both test strains and standard sensitive strain H37Rv: And sensitivity tests of second-line drugs (except pyrazinamide) were done: critical concentrations (μg/ml) for Tbl, EB, TH, RFP, CPM, KM, VM, and CS were 1, 1. 25, 40, 10, 20, 10, 40 and 20 μg /ml respectively. The results were read at the end of four weeks of incubation. The term ‘ growth’ has been used to mean the presence of 20 or more colonies on any drug-containing slope. The results of the isoniazid-sensitivity test s were expressed as ‘resistant ’ in the presence of growth on the slope containing 0.2μg isoniazid per ml. The PAS and streptomycin sensitivity test results were expressed as ‘resistance ratio’, namely, the MIC of the test strain divided by the MIC of strain H 37 Rv. The sensitivity of second line drugs was determined upon the presence or absence of growth on critical concentration of each drug.
Results
obtained were as follows: 1. Of the total of 132 patients, 92(69. 7% ) had no history of previous chemotherapy and the remaining 40 (30.3%) had a history of previous chemotherapy. 37.9% of the total of 132 had resistance to one or more standard drugs. items 2-6 refer to resistance to standard drugs only. 2. Of the 92 patients with no history of previous chemotherapy, 23.9% had resistance to one or more drugs: 16.9% had resistance to 1 drug only, 6.5% to 2 drugs and 6.5% to all 3 drugs 19.5% of the total patients showed resistance to isoniazid, 10.9% to PAS and 13.0% to streptomycin. 3. Of the 40 patients with a history of previous chemotherapy, 70% bad drug resistance to one or more drugs; 27.5% had resistance to 1 drug only, 15.0% to 2 drugs, and 27.5% to all 3 drugs. 70.0% of the total patients showed resistance to isoniazid, 40.0% to PAS and 30.0% to streptomycin. streptomycin. 4. Resistance to one or more drugs was found to increase with the diagnosed extent of disease, that is: 51.2% in the group ‘Far Advance' were found to be drug-resistant while only 31. 8% in the ‘Moderately Advanced' group and 26.8% in the ‘Minimal’ showed resistance. 5. The resistance to one or more drugs of patients in urban areas was found to be double that of patients in rural areas; 49.3% to 22.8% and the Urban patients also showed considerably higher resistance to all 3 drugs; 18. 7% to 5.3 %. 6. Referring to the drug resistance according to duration of previous chemotherapy, 16.7%, 55.5%, 60.0%, 100.0%, and 92. 8% in the groups treated during 1-6, 7-12, 13-18, 19-24, and over 25 months respectively, showed resistance to one or more drugs. 7. The great majority of strains showed noticeably higher sensitivity to second line drugs. Thiacçtazone showed appreciable resistance (46.9%). 8. An overall statistical comparison of drug resistance to standard drugs shown in the First and Second Surveys has revealed no particular difference in prevalence of drug resistance to one or more drugs but there was a marked increase in multi-drug resistance to isoniazid, PAS and streptomycin in the Second Survey as compared to the First. (table 8)


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next